Особенности диагностики и лечения хронической сердечной недостаточности у пациентов пожилого и старческого возраста. Мнение экспертов Общества специалистов по сердечной недостаточности, Российской ассоциации геронтологов и гериатров и Евразийской ассоциации терапевтов

Комитет экспертов: Беленков Юрий Никитич, Ардашев Андрей Вячеславович, Беграмбекова Юлия Леоновна, Виллевальде Светлана Вадимовна, Галявич Альберт Сарварович, Гарганеева Алла Анатольевна, Гендлин Геннадий Ефимович, Гиляревский Сергей Руджерович, Глезер Мария Генриховна, Драпкина Оксана Михайловна, Дупляков Дмитрий Викторович, Кобалава Жанна Давидовна, Козиолова Наталья Андреевна, Коротеев Алексей Васильевич, Никифоров Виктор Сергеевич, Остапенко Валентина Сергеевна, Перепеч Никита Борисович, Середенина Елена Михайловна,  Ситникова Мария Юрьевна, Скибицкий Виталий Викентьевич, Тарловская Екатерина Иосифовна, Фомин Игорь Владимирович,  Чесникова Анна Ивановна, Шарашкина Наталья Викторовна.

Цель настоящего документа  – заполнить пробелы доказательной медицины в вопросах ведения пациентов с ХСН пожилого и старческого возраста на основе анализа современных знаний и обобщенного опыта. Основные принципы диагностики и  лечения ХСН изложены в  Российских рекомендациях [1]. Представляемый документ содержит только концептуальные подходы и практические рекомендации по ведению пациентов с ХСН пожилого и старческого возраста. Он адресован ученым, планирующим и выполняющим исследования в области кардиологии и гериатрии, врачам, проходящим обучение в рамках непрерывного медицинского образования, аспирантам и ординаторам.

1. Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Арутюнов Г. П., Беграмбекова Ю. Л., Васюк Ю. А. и др. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18(1):3-40. DOI: 10.18087/rhfj.2017.1.2346

2. Folsom AR, Yamagishi K, Hozawa A, Chambless LE. Absolute and Attributable Risks of Heart Failure Incidence in Relation to Optimal Risk Factors. Circulation: Heart Failure. 2009;2(1):11-7. DOI: 10.1161/CIRCHEARTFAIL-URE.108.794933

3. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Archives ofInternal Medicine. 2001;161(7):996-1002. PMID: 11295963

4. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Executive Summary: Heart Disease and Stroke Statistics—2016 Update: A Report from the American Heart Association. Circulation. 2016;133(4):447-54. DOI: 10.1161/CIR.0000000000000366

5. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart Disease and Stroke Statistics—2011 Update: A Report from the American Heart Association. Circulation. 2011;123(4):e18-209. DOI: 10.1161/CIR.0b013e3182009701

6. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность хронической сердечной недостаточности в Европейской части Российской Федерации - данные ЭПОХА-ХСН (Часть II). Журнал Сердечная Недостаточность. 2006;7(3):112-5.

7. Артемьева Е. Г., Маленкова В. Ю., Фролова Е. В. Распространенность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011;(16):51-4.

8. Сергеева Е. М., Малишевский М. В., Васина А. А., Мищенко Т. А., Кузьмина Ю. С., Раемгулов Р. А. Лечение хронической сердечной недостаточности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и образование Урала. 2015;16(4):32-4.

9. Шакирова Р. М., Галявич А. С., Камалов Г. М. Распространенность сердечно-сосудистых заболеваний и сахарного диабета в республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная Недостаточность. 2005;6(2):72-3.

10. Смирнова Е. А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010;(2):78-83.

11. Фомин И. В., Беленков Ю. Н., Мареев В. Ю., Агеев Ф. Т., Бадин Ю. В., Галявич А. С. и др. Распространенность ХСН в Европейской части Российской Федерации - данные ЭПОХА-ХСН. Журнал Сердечная Недостаточность. 2006;7(1):4-7.

12. Фомин И. В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7-13. DOI: 10.15829/1560-4071-2016-8-7-13

13. Ahmed A. Clinical Manifestations, Diagnostic Assessment, and Etiology of Heart Failure in Older Adults. Clinics in Geriatric Medicine. 2007;23(1):11-30. DOI: 10.1016/j.cger.2006.08.002

14. Rich MW Kitzman D. Heart failure in octogenarians: a fundamentally different disease. AmericanJournal of Geriatric Cardiology. 2000;9(5 suppl1):97-104

15. Chaudhry SI, Wang Y, Gill TM, Krumholz HM. Geriatric Conditions and Subsequent Mortality in Older Patients With Heart Failure. Journal of the American College of Cardiology. 2010;55(4):309-16. DOI: 10.1016/j.jacc.2009.07.066

16. Lee SJ. Development and Validation of a Prognostic Index for 4-Year Mortality in Older Adults. JAMA. 2006;295(7):801. DOI: 10.1001/jama.295.7.801

17. Rich MW. Geriatric Heart Failure: A Call for Papers. Journal of Cardiac Failure. 2016;22(4):247-8. DOI: 10.1016/j.cardfail.2016.02.005

18. Huffman MD, Berry JD, Ning H, Dyer AR, Garside DB, Cai X et al. Lifetime Risk for Heart Failure Among White and Black Americans. Journal of the American College of Cardiology. 2013;61(14):1510-7. DOI: 10.1016/j.jacc.2013.01.022

19. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carne-thon M, Dai S et al. Executive Summary: Heart Disease and Stroke Statistics -2010 Update: A Report from the American Heart Association. Circulation. 2010;121(7):948-54. DOI: 10.1161/CIRCULATIONAHA.109.192666

20. Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM. Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003. Archives of Internal Medicine. 2008;168(4):418. DOI: 10.1001/archin-ternmed.2007.80

21. Jhund PS, MacIntyre K, Simpson CR, Lewsey JD, Stewart S, Redpath A et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515-23. DOI: 10.1161/CIRCULA-TIONAHA.108.812172

22. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KKL et al. Long-term trends in the incidence of and survival with heart failure. The New EnglandJournal ofMedicine. 2002;347(18):1397-402. DOI: 10.1056/NEJ-Moa020265

23. Roger VL. Trends in Heart Failure Incidence and Survival in a Community-Based Population. JAMA. 2004;292(3):344. DOI: 10.1001/jama.292.3.344

24. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Archives of Internal Medicine. 2002;162(15):1682-8. PMID: 12153370

25. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887-98. DOI: 10.1056/NEJ-Moa0801369

26. Spargias K, Manginas A, Pavlides G, Khoury M, Stavridis G, Rellia P et al. Transcatheter aortic valve implantation: first Greek experience. Hellenicjour-nal ofcardiology: HJC = Hellenike kardiologike epitheorese. 2008;49(6):397-407. PMID: 19110926

27. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical Profile and Natural History of453 Nonsurgically Managed Patients With Severe Aortic Stenosis. The Annals of Thoracic Surgery. 2006;82(6):2111-5. DOI: 10.1016/j.athorac-sur.2006.07.048

28. Avery CL, Loehr LR, Baggett C, Chang PP, Kucharska-Newton AM, Matsushita K et al. The Population Burden of Heart Failure Attributable to Modifiable Risk Factors. Journal of the American College of Cardiology. 2012;60(17):1640-6. DOI: 10.1016/j.jacc.2012.07.022

29. Olivieri F, Recchioni R, Marcheselli F, Abbatecola AM, Santini G, Borghet-ti G et al. Cellular senescence in cardiovascular diseases: potential age-related mechanisms and implications for treatment. Current Pharmaceutical Design. 2013;19(9):1710-9. PMID: 23061728

30. Oxenham H, Sharpe N. Cardiovascular aging and heart failure. EuropeanJour-nal of Heart Failure. 2003;5(4):427-34. PMID: 12921803

31. Abete P, Testa G, Della-Morte D, Gargiulo G, Galizia G, de Santis D et al. Treatment for chronic heart failure in the elderly: current practice and problems. Heart Failure Reviews. 2013;18(4):529-51. DOI: 10.1007/s10741-012-9363-6

32. Dharmarajan K, Rich MW. Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults. Heart Failure Clinics. 2017;13(3):417-26. DOI: 10.1016/j.hfc.2017.02.001

33. Pirmohamed A, Kitzman DW, Maurer MS. Heart failure in older adults: embracing complexity. Journal of geriatric cardiology: JGC. 2016;13(1):8-14. DOI: 10.11909/j.issn.1671-5411.2016.01.020

34. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure. 2016;18(8):891-975. DOI: 10.1002/ejhf.592

35. Ekundayo OJ, Howard VJ, Safford MM, McClure LA, Arnett D, Allman RM et al. Value of Orthopnea, Paroxysmal Nocturnal Dyspnea, and Medications in Prospective Population Studies of Incident Heart Failure. The American Journal of Cardiology. 2009;104(2):259-64. DOI: 10.1016/j.am-jcard.2009.03.025

36. Ahmed A. Chronic Heart Failure in Older Adults. Medical Clinics of North America. 2011;95(3):439-61. DOI: 10.1016/j.mcna.2011.02.001

37. Butman SM, Ewy GA, Standen JR, Kern KB, Hahn E. Bedside cardiovascular examination in patients with severe chronic heart failure: importance of rest or inducible jugular venous distension. Journal of the American College of Cardiology. 1993;22(4):968-74. PMID: 8409071

38. Sochowski RA, Dubbin JD, Naqvi SZ. Clinical and hemodynamic assessment of the hepatojugular reflux. The American Journal of Cardiology. 1990;66(12):1002-6. PMID: 2220606

39. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. The New England Journal of Medicine. 2001;345(8):574-81. DOI: 10.1056/NEJMoa010641

40. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F et al. The Obesity Paradox: Body Mass Index and Outcomes in Patients With Heart Failure. Archives of Internal Medicine. 2005;165(1):55. DOI: 10.1001/archinte.165.1.55

41. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P et al. Use of B-Type Natriuretic Peptide in the Evaluation and Management of Acute Dyspnea. New England Journal of Medicine. 2004;350(7):647-54. DOI: 10.1056/NEJMoa031681

42. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH et al. Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology. 2007;50(8):768-77. DOI: 10.1016/j.jacc.2007.04.064

43. Gerber Y, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Internal Medicine. 2015;175(6):996. DOI: 10.1001/jamainternmed.2015.0924

44. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome ofheart failure with preserved ej ection fraction. New EnglandJournal ofMedicine. 2006;355(3):251-9. DOI: 10.1056/NEJMoa052256

45. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A et al. Outcome of heart failure with preserved ejection fraction in a population-based study. The New EnglandJournal ofMedicine. 2006;355(3):260-9. DOI: 10.1056/NEJ-Moa051530

46. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management ofHeart Failure: A Report ofthe American College ofCardi-ology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society ofAmerica. Circulation. 2017;136(6):e137-61. DOI: 10.1161/CIR.0000000000000509

47. Glick D, deFilippi CR, Christenson R, Gottdiener JS, Seliger SL. Long-Term Trajectory of Two Unique Cardiac Biomarkers and Subsequent Left Ventricular Structural Pathology and Risk of Incident Heart Failure in Community-Dwelling Older Adults at Low Baseline Risk. JACC: Heart Failure. 2013;1(4):353-60. DOI: 10.1016/j.jchf.2013.04.007

48. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, Mc-MurrayJJV et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015;350(mar04 22):h910-h910. DOI: 10.1136/bmj.h910

49. Maisel A, Mueller C, Adams K, Anker SD, Aspromonte N, Cleland JGF et al. State of the art: Using natriuretic peptide levels in clinical practice. European Journal of Heart Failure. 2008;10(9):824-39. DOI: 10.1016/j.ej-heart.2008.07.014

50. Zaphiriou A, Robb S, MurrayThomas T, Mendez G, Fox K, McDonagh T et al. The diagnostic accuracy ofplasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: Results of the UK natriuretic peptide study. European Journal of Heart Failure. 2005;7(4):537-41. DOI: 10.1016/j.ejheart.2005.01.022

51. Fuat A, Murphy JJ, Hungin APS, Curry J, Mehrzad AA, Hetherington A et al. The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. The British Journal of General Practice: TheJournal ofthe Royal College of General Practitioners. 2006;56(526):327-33. PMID: 16638247

52. Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. Journal of Cardiac Failure. 2000;6(3):194-200. DOI: 10.1054/jcaf.2000.9676

53. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wil-son PA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. The Lancet. 1997;350(9088):1349-53. DOI: 10.1016/S0140-6736(97)06031-5

54. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. The American Journal of Medicine. 2001;111(4):274-9. PMID: 11566457

55. Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW. Clinical Utility of Three B-Type Natriuretic Peptide Assays for the Initial Diagnostic Assessment of New Slow-Onset Heart Failure. Journal of Cardiac Failure. 2011;17(9):729-34. DOI: 10.1016/j.cardfail.2011.04.013

56. Maisel AS, Krishnaswamy P, Nowak RM, McCordJ, HollanderJE, Duc P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis ofheart failure. The New England Journal ofMedicine. 2002;347(3):161-7. DOI: 10.1056/NEJMoa020233

57. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Kraus-er DG et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. The American Journal of Cardiology. 2005;95(8):948-54. DOI: 10.1016/j.amjcard.2004.12.032

58. Brenden CK, Hollander JE, Guss D, McCullough PA, Nowak R, Green G et al. Gray zone BNP levels in heart failure patients in the emergency department: Results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. American Heart Journal. 2006;151(5):1006-11. DOI: 10.1016/j.ahj.2005.10.017

59. Sarzani R, Spannella F, Giulietti F, Fedecostante M, Giordano P, Gattafoni P et al. NT-proBNP and Its Correlation with In-Hospital Mortality in the Very Elderly without an Admission Diagnosis of Heart Failure. PLOS ONE. 2016;11(4):e0153759. DOI: 10.1371/journal.pone.0153759

60. Berdague P, Caffin P-Y, Barazer I, Vergnes C, Sedighian S, Letrillard S et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiolog-ic diagnosis of acute dyspnea in elderly patients. American Heart Journal. 2006;151(3):690-8. DOI: 10.1016/j.ahj.2005.04.004

61. Luchner A, Behrens G, Stritzke J, Markus M, Stark K, Peters A et al. Long-term pattern ofbrain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors. European Journal of Heart Failure. 2013;15(8):859-67. DOI: 10.1093/eurjhf/hft048

62. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW Bailey KR, Burnett JC. Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology. 2002;40(5):976-82. PMID: 12225726

63. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R et al. Renal Function, Congestive Heart Failure, and Amino-Terminal Pro-Brain Natriuretic Peptide Measurement. Journal of the American College of Cardiology. 2006;47(1):91-7. DOI: 10.1016/j.jacc.2005.08.051

64. McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA et al. Measuring frailty in heart failure: A community perspective. American HeartJournal. 2013;166(4):768-74. DOI: 10.1016/j.ahj.2013.07.008

65. Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, D’Ambrosio D et al. Frailty predicts long-term mortality in elderly subj ects with chronic heart failure. European Journal of Clinical Investigation. 2005;35(12):723-30. DOI: 10.1111/j.1365-2362.2005.01572.x

66. Lupon J, Gonzalez B, Santaeugenia S, Altimir S, Urrutia A, Mas D et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Revista Espanola De Cardiologia. 2008;61(8):835-42. PMID: 18684366

67. Newman AB, Gottdiener JS, Mcburnie MA, Hirsch CH, Kop WJ, Tracy R et al. Associations of subclinical cardiovascular disease with frailty. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 86. 2001;56(3):M158-166. PMID: 11253157

68. Afilalo J, Karunananthan S, Eisenberg MJ, Alexander KP, Bergman H. Role of Frailty in Patients With Cardiovascular Disease. The American Journal of Cardiology. 2009;103(11):1616-21. DOI: 10.1016/j.amjcard.2009.01.375

69. Fialova D, Onder G. Medication errors in elderly people: contributing factors and future perspectives. British Journal of Clinical Pharmacology. 2009;67(6):641-5. DOI: 10.1111/j.1365-2125.2009.03419.x

70. Cudmore V, Henn P, O’Tuathaigh CMP, Smith S. Age-Related Hearing Loss and Communication Breakdown in the Clinical Setting. JAMA Otolaryngology-Head & Neck Surgery. 2017;143(10):1054. DOI: 10.1001/jamao-to.2017.1248

71. Wattamwar K, Qian ZJ, Otter J, Leskowitz MJ, Caruana FF, Siedlecki B et al. Increases in the Rate of Age-Related Hearing Loss in the Older Old. JAMA Otolaryngology-Head & Neck Surgery. 2017;143(1):41. DOI: 10.1001/ja-maoto.2016.2661

72. Committee on Accessible and Affordable Hearing Health Care for Adults, Board on Health Sciences Policy, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. Hearing Health Care for Adults: Priorities for Improving Access and Affordability. -Washington, D.C.: National Academies Press; Editors: Blazer, DG, Domnitz, S, Liverman, CT . ISBN 978-0-309-43926-8

73. Senn N, Monod S. Development of a Comprehensive Approach for the Early Diagnosis of Geriatric Syndromes in General Practice. Frontiers in Medicine. 2015;2. DOI: 10.3389/fmed.2015.00078

74. Fried TR, McGraw S, Agostini JV, Tinetti ME. Views of Older Persons with Multiple Morbidities on Competing Outcomes and Clinical Decision-Making: MULTIPLE MORBIDITIES AND DECISION-MAKING. Journal of the American Geriatrics Society. 2008;56(10):1839-44. DOI: 10.1111/j.1532-5415.2008.01923.x

75. Study design ofASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial. Contemporary Clinical Trials. 2013;36(2):555-64. DOI: 10.1016/j.cct.2013.09.014

76. Katz S, Akpom CA. A Measure of Primary Sociobiological Functions. International Journal of Health Services. 1976;6(3):493-508. DOI: 10.2190/UURL-2RYU-WRYD-EY3K

77. Balke B. A simple field test for the assessment of physical fitness. Rep 636. [Report]. Civil Aeromedical Research Institute (U.S.). 1963;(53):1-8. PMID: 14131272

78. Katz S, Downs TD, Cash HR, Grotz RC. Progress in development of the index ofADL. The Gerontologist. 1970;10(1):20-30. PMID: 5420677

79. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. The Gerontologist. 1969;9(3):179-86. PMID: 5349366

80. Захаров В. В. Нейропсихологические тесты. Необходимость и возможность применения. Consilium Medicum. 2011;13(2):98-106.

81. Fleming KC, Evans JM, Weber DC, Chutka DS. Practical Functional Assessment of Elderly Persons: A Primary-Care Approach. Mayo Clinic Proceedings. 1995;70(9):890-910. DOI: 10.1016/S0025-6196(11)63949-9

82. Nordin E, Lindelof N, Rosendahl E, Jensen J, Lundin-olsson L. Prognostic validity of the Timed Up-and-Go test, a modified Get-Up-and-Go test, staff’s global judgement and fall history in evaluating fall risk in residential care facilities. Age and Ageing. 2008;37(4):442-8. DOI: 10.1093/ageing/afn101

83. Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. Journal of Geriatric Physical Therapy (2001). 2006;29(2):64-8. PMID: 16914068

84. Tadjibaev P, Frolova E, Gurina N, DegryseJ, Vaes B. The relationship between physical performance and cardiac function in an elderly Russian cohort. Archives of Gerontology and Geriatrics. 2014;59(3):554-61. DOI: 10.1016/j.archger.2014.08.003

85. Мареев В. Ю., Арутюнов Г. П., Асташкин Е. И., Вёрткин А. Л., Глезер М. Г., Лопатин Ю. М. и др. Острая декомпенсированная сердечная недостаточность. Согласованная позиция российских экспертов - 2014. Журнал Сердечная Недостаточность. 2014;15(5):321-36. DOI: 10.18087/rhfj.2014.5.2024

86. Мареев Ю. В., Герасимова В. В., Горюнова Т. В., Петрухина А. А., Даниелян М. О., Капанадзе Л. Г. и др. Факторы, определяющие прогноз при хронической сердечной недостаточности: роль ширины и морфологии комплекса QRS. Журнал Сердечная Недостаточность. 2012;13(5):255-66.

87. Brach JS, Simonsick EM, Kritchevsky S, Yaffe K, Newman AB, for the Health, Aging and Body Composition Study Research Group. The Association Between Physical Function and Lifestyle Activity and Exercise in the Health, Aging and Body Composition Study: PHYSICAL ACTIVITY AND PHYSICAL FUNCTION. Journal of the American Geriatrics Society. 2004;52(4):502-9. DOI: 10.1111/j.1532-5415.2004.52154.x

88. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W et al. Health related quality oflife in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart (British Cardiac Society). 2002;87(3):235-41. PMID: 11847161

89. Johnstone MJ. Quality versus quantity oflife: who should decide? The Australian Journal ofAdvanced Nursing: A Quarterly Publication of the Royal Australian Nursing Federation. 1988;6(1):30-7. PMID: 2980628

90. Foebel AD, Liperoti R, Gambassi G, Gindin J, Ben Israel J, Bernabei R et al. Prevalence and Correlates of Cardiovascular Medication Use Among Nursing Home Residents With Ischemic Heart Disease: Results From the SHELTER Study. Journal of the American Medical Directors Association. 2014;15(6):410-5. DOI: 10.1016/j.jamda.2013.12.085

91. Onder G, Liperoti R, Foebel A, Fialova D, Topinkova E, van der Roest HG et al. Polypharmacy and Mortality Among Nursing Home Residents With Advanced Cognitive Impairment: Results From the Shelter Study. Journal of the American Medical Directors Association. 2013;14(6):450.e7-450.e12. DOI: 10.1016/j.jamda.2013.03.014

92. Forman DE, Arena R, Boxer R, Dolansky MA, Eng JJ, Fleg JL et al. Prioritizing Functional Capacity as a Principal End Point for Therapies Oriented to Older Adults With Cardiovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation. 2017;135(16):e894-918. DOI: 10.1161/CIR.0000000000000483

93. Blinderman CD, Homel P, BillingsJA, Portenoy RK, Tennstedt SL. Symptom Distress and Quality of Life in Patients with Advanced Congestive Heart Failure. Journal of Pain and Symptom Management. 2008;35(6):594-603. DOI: 10.1016/j.jpainsymman.2007.06.007

94. Prybys KM, Melville KA, Hanna JR. Polypharmacy in the Elderly: Clinical Challenges in Emergency Practice - Part I. 2002-05-20. AHC Media: Continuing Medical Education Publishing. https://www.reliasmedia.com/ articles/119992-polypharmacy-in-the-elderly-clinical-challenges-in-emer-gency-practice-part-i. [Internet] 2002. Available at: https: //www.reliasmedia.com/articles/119992-polypharmacy-in-the-elderly-clinical-challenges-in-emergency-practice-part-i

95. Nahin RL, FitzpatrickAL, WilliamsonJD, Burke GL, DeKosky ST, Furberg C et al. Use ofHerbal Medicine and Other Dietary Supplements in CommunityDwelling Older People: Baseline Data from the Ginkgo Evaluation ofMemo-ry Study. Journal of the American Geriatrics Society. 2006;54(11):1725-35. DOI: 10.1111/j.1532-5415.2006.00942.x

96. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional Medicine in the United States - Prevalence, Costs, and Patterns of Use. New England Journal of Medicine. 1993;328(4):246-52. DOI: 10.1056/NEJM199301283280406

97. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society. 2015;63(11):2227-46. DOI: 10.1111/jgs.13702

98. Wickop B, Harterich S, Sommer C, Daubmann A, Baehr M, Langebrake C. Potentially Inappropriate Medication Use in Multimorbid Elderly Inpatients: Differences Between the FORTA, PRISCUS and STOPP Ratings. Drugs - Real World Outcomes. 2016;3(3):317-25. DOI: 10.1007/s40801-016-0085-2

99. Gallagher PF, O’Connor MN, O’Mahony D. Prevention of Potentially Inappropriate Prescribing for Elderly Patients: A Randomized Controlled Trial Using STOPP/START Criteria. Clinical Pharmacology & Therapeutics. 2011;89(6):845-54. DOI: 10.1038/clpt.2011.44

100. Cahir C, Bennett K, Teljeur C, Fahey T. Potentially inappropriate prescribing and adverse health outcomes in community dwelling older patients: Potentially inappropriate prescribing in older populations. British Journal of Clinical Pharmacology. 2014;77(1):201-10. DOI: 10.1111/bcp.12161

101. Mueller SK, Sponsler KC, Kripalani S, SchnipperJL. Hospital-Based Medication Reconciliation Practices: A Systematic Review. Archives ofInternal Medicine. 2012;172(14). DOI: 10.1001/archinternmed.2012.2246

102. Kanaan AO, Donovan JL, Duchin NP, Field TS, Tjia J, Cutrona SL et al. Adverse Drug Events After Hospital Discharge in Older Adults: Types, Severity, and Involvement of Beers Criteria Medications. Journal of the American Geriatrics Society. 2013;61(11):1894-9. DOI: 10.1111/jgs.12504

103. Vetrano DL, Lattanzio F, Martone AM, Landi F, Brandi V, Topinkova E et al. Treating heart failure in older and oldest old patients. Current Pharmaceutical Design. 2015;21(13):1659-64. PMID: 25633115

104. Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal. 2006;27(19):2338-45. DOI: 10.1093/eurheartj/ehl250

105. Little WC, Wesley-Farrington DJ, Hoyle J, Brucks S, Robertson S, Kitzman DW et al. Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction. Journal ofCardiovascular Pharmacology. 2004;43(2):288-93. PMID: 14716219

106. Groban L, Pailes NA, Bennett CDL, Carter CS, Chappell MC, Kitzman DW et al. Growth hormone replacement attenuates diastolic dysfunction and cardiac angiotensin II expression in senescent rats. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2006;61(1):28-35. PMID: 16456192

107. Lasocki S, Iglarz M, Seince P-F, Vuillaumier-Barrot S, Vicaut E, Henrion D et al. Involvement of renin-angiotensin system in pressure-flow relationship: role of angiotensin-converting enzyme gene polymorphism. Anesthesiology. 2002;96(2):271-5. PMID: 11818755

108. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777-81. DOI: 10.1016/S0140-6736(03)14285-7

109. Lund LH, Claggett B, LiuJ, Lam CS, Jhund PS, Rosano GM et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum: Candesar-tan across the ejection fraction spectrum. European Journal of Heart Failure. 2018;20(8):1230-9. DOI: 10.1002/ejhf.1149

110. McMurrayJJV Packer M, Desai AS, GongJ, Lefkowitz MP, Rizkala AR et al. Angiotensin-niprilysin Inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993-1004. DOI: 10.1056/NEJ-Moa1409077

111. Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal. 2005;26(3):215-25. DOI: 10.1093/eurheartj/ehi115

112. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Rough-ton M et al. Beta-Blockade with Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology. 2009;53(23):2150-8. DOI: 10.1016/j.jacc.2009.02.046

113. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal. 2018;39(1):26-35. DOI: 10.1093/eurheartj/ehx564

114. Upadhya B, Taffet GE, Cheng CP, Kitzman DW. Heart failure with preserved ejection fraction in the elderly: scope of the problem.Journal ofMolecular and Cellular Cardiology. 2015;83:73-87. DOI: 10.1016/j.yjmcc.2015.02.025

115. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine. 1999;341(10):709-17. DOI: 10.1056/NEJM199909023411001

116. Krum H, Shi H, Pitt B, McMurray J, Swedberg K, van Veldhuisen DJ et al. Clinical Benefit of Eplerenone in Patients With Mild Symptoms of Systolic Heart Failure Already Receiving Optimal Best Practice Background Drug Therapy: Analysis of the EMPHASIS-HF Study. Circulation: Heart Failure. 2013;6(4):711-8. DOI: 10.1161/CIRCHEARTFAILURE.112.000173

117. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOP-CAT) trial. Circulation. 2015;131(1):34-42. DOI: 10.1161/CIRCULA-TIONAHA.114.013255

118. Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016;37(5):455-62. DOI: 10.1093/eurheartj/ehv464

119. Kotecha D. Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials. [Internet] 2017. Available at: http://congress365.escardio.org/Presentation/162249#.WjYgFFVl_cs

120. Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance oflow doses and low serum concentrations. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2007;62(3):323-9. PMID: 17389731

121. Ahmed A, Rich MW, FlegJL, Zile MR, YoungJB, Kitzman DW et al. Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114(5):397-403. DOI: 10.1161/CIRCULATIONAHA.106.628347

122. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. European Heart Journal. 2006;27(2):178-86. DOI: 10.1093/eurheartj/ehi687

123. Lalia AZ, Dasari S, Robinson MM, Abid H, Morse DM, Klaus KA et al. Influence of omega-3 fatty acids on skeletal muscle protein metabolism and mitochondrial bioenergetics in older adults. Aging. 2017; DOI: 10.18632/ag-ing.101210

124. Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C et al. Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology. 2018;3(4):288. DOI: 10.1001/jamacardio.2017.5365

125. FerreiraJP, Duarte K, Pfeffer MA, McMurrayJJV, Pitt B, Dickstein K et al. Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction: BP and outcomes in myocardial infarction. European Journal of Heart Failure. 2018;20(2):323-31. DOI: 10.1002/ejhf.1131

126. Ревишвили А. Ш., Шляхто Е. В., Попов С. В., Покушалов Е. А., Сулимов В. А., Голицин С. П. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. - М.: ВНОА; 702 p. ISBN 978-5-9500922-0-6

127. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134(13):e282-93. DOI: 10.1161/CIR.0000000000000435

128. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment ofacute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129-200. DOI: 10.1093/eurheartj/ ehw128

129. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010;363(17):1597-607. DOI: 10.1056/NEJMoa1008232

130. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberg-er L et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New EnglandJournal ofMedicine. 2005;352(15):1539-49. DOI: 10.1056/NEJMoa050496

131. Nielsen JC, Thomsen PEB, Hojberg S, Moller M, Vesterlund T, Dalsgaard D et al. A comparison of single-lead atrial pacing with dual-chamber pacing in sick sinus syndrome. European Heart Journal. 2011;32(6):686-96. DOI: 10.1093/eurheartj/ehr022

132. Lamas GA, Lee KL, Sweeney MO, Silverman R, Leon A, Yee R et al. Ventricular Pacing or Dual-Chamber Pacing for Sinus-Node Dysfunction. New England Journal of Medicine. 2002;346(24):1854-62. DOI: 10.1056/NEJ-Moa013040

133. Andersen HR, Thuesen L, Bagger JP, Vesterlund T, Thomsen PE. Prospective randomised trial ofatrial versus ventricular pacing in sick-sinus syndrome. Lancet (London, England). 1994;344(8936):1523-8. PMID: 7983951

134. Heldman D, Mulvihill D, Nguyen H, Messenger JC, Rylaarsdam A, Evans K et al. True incidence of pacemaker syndrome. Pacing and clinical electrophysiology: PACE. 1990;13(12 Pt 2):1742-50. PMID: 1704534

135. Wilkoff BL, Kudenchuk PJ, Buxton AE, Sharma A, CookJR, Bhandari AK et al. The DAVID (Dual Chamber and VVI Implantable Defibrillator) II Trial. Journal of the American College of Cardiology. 2009;53(10):872-80. DOI: 10.1016/j.jacc.2008.10.057

136. Tang ASL, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. New England Journal of Medicine. 2010;363(25):2385-95. DOI: 10.1056/NEJ-Moa1009540

137. Santangeli P, Di Biase L, Russo AD, Casella M, Bartoletti S, Santarelli P et al. Meta-analysis: Age and Effectiveness of Prophylactic Implantable Cardioverter-Defibrillators. Annals of Internal Medicine. 2010;153(9):592. DOI: 10.7326/0003-4819-153-9-201011020-00009

138. Steinberg BA, Al-Khatib SM, Edwards R, Han J, Bardy GH, Bigger JT et al. Outcomes of Implantable Cardioverter-Defibrillator Use in Patients with Comorbidities. JACC: Heart Failure. 2014;2(6):623-9. DOI: 10.1016/j.jchf.2014.06.007

139. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videb$k L, Korup E et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine. 2016;375(13):1221-30. DOI: 10.1056/NEJ-Moa1608029

140. TIME Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. The Lancet. 2001;358(9286):951-7. DOI: 10.1016/S0140-6736(01)06100-1

141. Pfisterer M. Long-Term Outcome in Elderly Patients With Chronic Angina Managed Invasively Versus by Optimized Medical Therapy: Four-Year Follow-Up of the Randomized Trial of Invasive Versus Medical Therapy in Elderly Patients (TIME). Circulation. 2004;110(10):1213-8. DOI: 10.1161/01.CIR.0000140983.69571.BA

142. Wenger NK, Helmy T, Patel AD, Lerakis S. Evidence-based management of coronary artery disease in the elderly - current perspectives. MedGenMed: Medscape General Medicine. 2005;7(2):75. PMID: 16369453

143. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA et al. Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic DysfunctionClinical Perspective: An Analysis ofthe Extended Follow-Up ofthe STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134(18):1314-24. DOI: 10.1161/CIRCULATIONAHA.116.024800

144. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. European HeartJournal. 2017;38(36):2739-91. DOI: 10.1093/eurheartj/ehx391

145. Арутюнов Г. П., Колесникова Е. А., Беграмбекова Ю. Л., Орлова Я. А., Рылова А. К., Аронов Д. М. и др. Рекомендации по назначению физических тренировок пациентам с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2017;18(1):41-66. DOI: 10.18087/rhfj.2017.1.2339

146. Iolascon G, Di Pietro G, Gimigliano F, Mauro GL, Moretti A, Giamattei MT et al. Physical exercise and sarcopenia in older people: position paper of the Italian Society of Orthopaedics and Medicine (OrtoMed). Clinical Cases in Mineral and Bone Metabolism: The Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. 2014;11(3):215-21. PMID: 2556865

147. Орлова Я.А. Особенности физической реабилитации пожилых пациентов с ХСН. Журнал Сердечная Недостаточность. 2016;17(5):365-75. DOI: 10.18087/rh-fj.2016.5.2295

148. McMurrayJJJV Improving outcomes in heart failure: a personal perspective. European Heart Journal. 2015;36(48):3467-70. DOI: 10.1093/eurheartj/ ehv565

149. Brullmann S, Dichtl W, Paoli U, Haegeli L, Schmied C, SteffelJ et al. Comparison ofBenefit and Mortality of Implantable Cardioverter-Defibrillator Therapy in Patients Aged >75 Years Versus Those <75 Years. The AmericanJournal of Cardiology. 2012;109(5):712-7. DOI: 10.1016/j.amjcard.2011.10.030

150. Dev S, Abernethy AP, Rogers JG, O’Connor CM. Preferences of people with advanced heart failure—a structured narrative literature review to inform decision making in the palliative care setting. American Heart Journal. 2012;164(3):313-319.e5. DOI: 10.1016/j.ahj.2012.05.023

151. McKelvie RS, Moe GW Cheung A, Costigan J, Ducharme A, Estrella-Hold-er E et al. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care. CanadianJournal of Cardiology. 2011;27(3):319-38. DOI: 10.1016/j.cjca.2011.03.011

152. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhauser KE, Fiuzat M et al. Palliative Care in Heart Failure. Journal of the American College of Cardiology. 2017;70(3):331-41. DOI: 10.1016/j.jacc.2017.05.030

153. Lindvall C, Hultman TD, Jackson VA. Overcoming the Barriers to Palliative Care Referral for Patients With Advanced Heart Failure. Journal of the American Heart Association. 2014;3(1). DOI: 10.1161/JAHA.113.000742

154. Walke LM, Gallo WT, Tinetti ME, Fried TR. The Burden of Symptoms Among Community-Dwelling Older Persons With Advanced Chronic Disease. Archives of Internal Medicine. 2004;164(21):2321. DOI: 10.1001/archinte.164.21.2321

155. Bekelman DB, Nowels CT, Allen LA, Shakar S, KutnerJS, Matlock DD. Outpatient Palliative Care for Chronic Heart Failure: A Case Series. Journal ofPal-liative Medicine. 2011;14(7):815-21. DOI: 10.1089/jpm.2010.0508

156. Heo S, Doering LV, Widener J, Moser DK. Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. American Journal of Critical Care: An Official Publication, American Association of Critical-Care Nurses. 2008;17(2):124-32. PMID: 18310649

157. Bekelman DB, RumsfeldJS, Havranek EP, Yamashita TE, Hutt E, Gottlieb SH et al. Symptom Burden, Depression, and Spiritual Well-Being: A Comparison of Heart Failure and Advanced Cancer Patients. Journal of General Internal Medicine. 2009;24(5):592-8. DOI: 10.1007/s11606-009-0931-y

158. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):1810-52. DOI: 10.1161/CIR.0b013e31829e8807

159. Reinke LF, Slatore CG, Uman J, Udris EM, Moss BR, Engelberg RA et al. Patient-Clinician Communication about End-of-Life Care Topics: Is Anyone Talking to Patients with Chronic Obstructive Pulmonary Disease? Journal of Palliative Medicine. 2011;14(8):923-8. DOI: 10.1089/jpm.2010.0509

160. Williams SG, Wright DJ, Marshall P, Reese A, Tzeng B-H, Coats AJS et al. Safety and potential benefits of low dose diamorphine during exercise in patients with chronic heart failure. Heart (British Cardiac Society). 2003;89(9):1085-6. PMID: 12923038

161. Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. Journal of the American College of Cardiology. 1997;29(1):147-52. PMID: 8996307

162. Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure - a pilot study. EuropeanJournal ofHeart Failure. 2002;4(6):753-6. PMID: 12453546

163. Ekstrom M, Nilsson F, Abernethy AA, Currow DC. Effects of Opioids on Breathlessness and Exercise Capacity in Chronic Obstructive Pulmonary Disease. A Systematic Review. Annals of the American Thoracic Society. 2015;12(7):1079-92. DOI: 10.1513/AnnalsATS.201501-034OC

164. Ekstrom MP, Bornefalk-Hermansson A, Abernethy AP, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ. 2014;348(jan30 2):g445-g445. DOI: 10.1136/bmj.g445

165. Bradley TD, Logan AG, Kimoff RJ, Series F, Morrison D, Ferguson K et al. Continuous Positive Airway Pressure for Central Sleep Apnea and Heart Failure. New England Journal of Medicine. 2005;353(19):2025-33. DOI: 10.1056/NEJMoa051001

166. Beniaminovitz A, Lang CC, LaManca J, Mancini DM. Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. Journal of the American College of Cardiology. 2002;40(9):1602-8. PMID: 12427412

167. Gysels MH, Higginson IJ. Caring for a person in advanced illness and suffering from breathlessness at home: Threats and resources. Palliative and Supportive Care. 2009;7(02):153. DOI: 10.1017/S1478951509000200

168. Evangelista LS, Moser DK, Westlake C, Pike N, Ter-Galstanyan A, Dracup K. Correlates of fatigue in patients with heart failure. Progress in Cardiovascular Nursing. 2008;23(1):12-7. PMID: 18326992

169. Quittan M, Wiesinger GF, Sturm B, Puig S, Mayr W Sochor A et al. Improvement ofthigh muscles by neuromuscular electrical stimulation in patients with refractory heart failure: a single-blind, randomized, controlled trial. Ameri-canJournal of Physical Medicine & Rehabilitation. 2001;80(3):206-14; quiz 215-6, 224. PMID: 11237275

170. Goodlin SJ, Wingate S, Albert NM, Pressler SJ, Houser J, Kwon J et al. Investigating Pain in Heart Failure Patients: The Pain Assessment, Incidence, and Nature in Heart Failure (PAIN-HF) Study. Journal of Cardiac Failure. 2012;18(10):776-83. DOI: 10.1016/j.cardfail.2012.07.007

171. Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016;i4857. DOI: 10.1136/bmj.i4857

172. Zis P, Daskalaki A, Bountouni I, Sykioti P, Varrassi G, Paladini A. Depression and chronic pain in the elderly: links and management challenges. Clinical Interventions in Aging. 2017;Volume 12:709-20. DOI: 10.2147/CIA.S113576

173. De Smedt RHE, Denig P, Haaijer-Ruskamp FM, Jaarsma T. Perceived medication adverse effects and coping strategies reported by chronic heart failure patients. InternationalJournal of Clinical Practice. 2009;63(2):233-42. DOI: 10.1111/j.1742-1241.2008.01954.x

174. Sullivan M, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. Journal of Cardiac Failure. 2004;10(5):390-6. PMID: 15470649

175. Gottlieb SS, Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N et al. A double-blind placebo-controlled pilot study of controlled-release paroxetine on depression and quality oflife in chronic heart failure. American Heart Journal. 2007;153(5):868-73. DOI: 10.1016/j.ahj.2007.02.024

176. O’Connor CM, Jiang W Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD et al. Safety and Efficacy of Sertraline for Depression in Patients with Heart Failure. Journal of the American College of Cardiology. 2010;56(9):692-9. DOI: 10.1016/j.jacc.2010.03.068

177. Bekelman D, Sullivan MD. Depression and Anxiety in Patients with Chronic Heart Failure.

178. Kirby D, Ames D. Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. International Journal of Geriatric Psychiatry. 2001;16(5):484-93. PMID: 11376464

179. Glassman AH. Cardiovascular Effects of Tricyclic Antidepressants. Annual Review of Medicine. 1984;35(1) :503-11. DOI: 10.1146/annurev.me.35.020184.002443

180. Goldberg RJ, Capone RJ, Hunt JD. Cardiac complications following tricyclic antidepressant overdose. Issues for monitoring policy. JAMA. 1985;254(13):1772-5. PMID: 4032678

181. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Current Medicinal Chemistry. 1999;6(6):469-80. PMID: 10213794

182. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al. Aripipra-zole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. The Journal of Pharmacology and Experimental Therapeutics. 2002;302(1):381-9. PMID: 12065741

183. Jordan S, Koprivica V Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology. 2002;441(3):137-40. PMID: 12063084